Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 7/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.34 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591223 | 0.92 | NMT1 (0.41) | NAA50APLNRACENMT2NMT1 | |
| SCHEMBL31593298 | 0.89 | APLNR (0.41) | NAA50APLNRNMUR2NMUR1PLK1 | |
| SCHEMBL31468806 | 0.88 | APLNR (0.44) | APLNR | |
| SCHEMBL29408366 | 0.88 | APLNR (0.41) | APLNRACENMUR2NMUR1PLK1 | |
| SCHEMBL31593272 | 0.88 | PLK1 (0.38) | NAA50APLNRNMUR2NMUR1PLK1 | |
| SCHEMBL30379247 | 0.88 | PLK1 (0.41) | NAA50APLNRACEACE2PLK1 | |
| SCHEMBL31593299 | 0.87 | ACE (0.44) | APLNRACENMT2NMT1 | |
| SCHEMBL30918794 | 0.87 | APLNR (0.39) | NAA50APLNR | |
| SCHEMBL31257058 | 0.86 | PLK1 (0.40) | NAA50APLNRACEACE2NMUR2 | |
| SCHEMBL31593308 | 0.85 | OPRM1 (0.41) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030099-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | NAA50 4114/4885APLNR 64/4885ACE 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.